September 4, 2014
Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy
Med Oncol. (2014) 31: 163. https://doi.org/10.1007/s12032-014-0163-9.
Soley Bayraktar, Melanie Royce, Lisette Stork-Sloots, Femke de Snoo, Stefan Glück
The overall pCR plus npCR rate was 25 % (30/122). Stratified by BluePrint/MammaPrint, patients of HER2 type had the best response (59 %), while luminal A (7 %) and B (9 %) subtypes had the poorest. The pCR plus npCR rate in patients classified with PAM50 assay was 76 % in HER2 type, 10 % in luminal A type, and 5 % in luminal B type.